Introduction
Alport syndrome (AS)' is a progressive hereditary nephritis associated with sensorineural hearing loss and often ocular lesions (lenticonus and/or macular lesions) ( 1 ). Phenotypic heterogeneity stems from the rate ofprogression to end-stage renal disease (ESRD), with two predominant clinical types, juve-1. Abbreviations used in this paper: AS, Alport syndrome; DMD, Duchenne muscular dystrophy; ESRD, end-stage renal disease; GBM, glomerular basement membrane; NC, noncollagenous.
nile-onset ESRD and adult-onset ESRD, and from the association or not with extrarenal symptoms (2) . Its mode of inheritance is mainly X-linked dominant with an estimated incidence of 1/5,000. Autosomal recessive and dominant forms have also been reported (3) . Characteristic ultrastructural changes of the glomerular basement membrane (GBM) include thickening with splitting ofthe lamina densa, whereas the GBM may be uniformily thin in some AS patients (4) . Furthermore, immunohistochemical studies with antibodies directed against the noncollagenous (NC) domain of type IV collagen showed impaired GBM antigenicity in most AS patients (4, 5) , suggesting a primary defect in type IV collagen, the major GBM structural component. Type IV collagen has a triple-helical structure composed of three a chains. These a chains contain long Gly-X-Y repeat sequences that form the collagenous domain, interrupted 21-23 times by non collagenous sequences. At the carboxy-terminal end, each a chain has a highly conserved 26-28-kD NC domain, involved in the folding of a chains into the triple helix and in the formation of intermolecular cross-links through cysteine residues. Six different types of a(IV) chains have been described. The a 1 (IV) and a2 (IV) are found in most basement membranes and are encoded by head-to-head genes located on the long arm of chromosome 13 (6) . The a3, a4, and a5(IV) chains have a more restricted distribution, mainly in specialized basement membranes of the kidney, ear, and eye (7, 8) . The genes encoding for the a3 and a4(IV) chains have been partially cloned and mapped side by side in 2q35-q37 (9) . The human COL4A5 gene encoding the a5(IV) chain has been mapped to Xq22 ( 10) , where linkage analysis has mapped the AS locus ( 11).
Several major gene rearrangements and point mutations in this gene have been found in AS patients ( 12) . No extensive study on a large population of X-linked AS families has yet been performed to assess the frequency and extent ofdeletions. Very recently a sixth a(IV) chain encoding gene (COL4A6) has been cloned and shown to be located head to head with COL4A5 (13) . Data regarding to its involvement in AS are still lacking.
In this article, we report the characterization of major COL4A5 defects in 88 X-linked AS families. We found 14 different deletions, providing a deletion rate of 16% in the gene in this patient population. Because the mRNA represents the actual template for translation, the nature of a defect at the mRNA level can correlate better with disease severity than does the putative mRNA structure extrapolated from genomic data. Because the expression of the COL4A5 gene is restricted to specific tissues, none of which being readily obtained, we took advantage ofthe illegitimate transcription ofhighly tissuespecific genes in easily accessible cells such as lymphocytes ( 14) to characterize pathological COL4A5 transcripts in AS patients.
Methods
Patients. 88 unrelated male patients have been studied. All had hematuria. In each family, the pedigree was compatible with an X-linked transmission, with no male-to-male transmission and a more severe disease in males. 84 patients had classical AS. According to Flinter et al. (15) , three ofthe following four diagnostic criteria are required for AS: positive family history of hematuria, with or without progression to ESRD, sensorineural deafness in the proband or in an affected member of the family, typical ocular changes (lenticonus and/or macular changes), and GBM ultrastructural changes. In addition, we took into account a fifth criterion, absence by immunohistochemistry of the a3 and a4 chains of type IV collagen in the GBM, which, in our experience, is a specific marker for AS (4) . At least three ofthese criteria were present in 53 patients. We also considered as affected 31 patients who fulfilled only two criteria: 24 had typical progressive hereditary nephritis with hearing loss, but they did not undergo renal biopsy; the others were young children without extrarenal symptoms at the time of renal biopsy. Analysis of the rate of progression to ESRD, when possible, allowed the distinction between juvenile type (57 cases, with an average age at ESRD of 20 yr) and adult type (10 cases, with an average age at ESRD of 42 yr). One patient belongs to a large family with an intermediate type ofAS, characterized by an average age ofESRD of31 yr, ranging from 14 to 41. 16 patients aged 5-15 yr were unclassified because oftheir young age and ofthe absence ofother affected males in their family. However, 15 of these 16 patients developed hematuria and proteinuria before the age of6 yr, with early occurrence ofdeafness in five of them and are probably affected with the juvenile type of AS. One patient had megathrombocytopenia and three had diffuse esophageal leiomyomatosis.
Four patients had progressive hereditary nephritis without any extrarenal symptoms.
Transplantation has been performed in the proband and/or in affected male relatives of44 kindreds. One patient withjuvenile AS developed anti-GBM antibodies and crescentic glomerulonephritis 5 mo after transplantation, leading to the loss of the graft. No other affected patient in his family has been transplanted.
Immunohistochemical study. Indirect immunofluorescence study ofthe glomerular distribution ofthe a3 and a4 chains oftype IV collagen, and of the al (IV) chain (control), was performed in 30 AS patients. Eight normal kidneys not used for transplantation, and 45 renal biopsy specimens of patients presenting various types of acquired glomerulopathies, were tested as controls.
The monoclonal anti-a3(IV) antibody, mAb 17, a gift from J. Wieslander (University ofLund, Sweden), recognizes the very anionic 28-kD monomer extracted from GBM collagen, and corresponding to the NCl domain of the a3(IV) chain. The monoclonal anti-a4 antibody, mAb 85, a gift from M. Kleppel (University of Minnesota), recognizes the more neutral 28-kD monomer corresponding to the NC I domain of the a4(IV) chain. The NC I specificities of these antibodies have been previously established (16, 17) . The monoclonal anti-al(IV) antibody is directed against the NCI domain of the al (IV) chain (Wieslab, Lund, Sweden). Affinity-purified FITC-conjugated sheep anti-mouse IgG were obtained from Silenus (Hawthorn, Victoria, Australia).
Serial acetone-fixed, cryostate sections of snap-frozen kidney tissue were stained with primary antibodies followed by FITC-conjugated secondary antibodies. Control sections, directly incubated with the secondary antibodies, were negative. Positive labeling of renal basement membranes with the anti-al (IV) antibody was observed in AS patients as in controls. The a3 and a4 chains of type IV collagen were normally present in the GBM and the distal tubular basement membrane of controls and of eight AS patients. Conversely, no labeling could be detected in 22 AS patients.
Southern blotting analysis. Genomic DNA was isolated from peripheral blood lymphocytes, digested using four enzymes (PstI, EcoRI, MspI, and TaqI), and hybridized successively with a set of cDNA probes spanning the entire COL4A5 cDNA. The cDNA probes included respectively, from the 5' to the 3' end, the following clones: JZ4, HT14-1, HT14-2, and HT14-3, which contain the coding sequence for the 5' untranslated region and the amino acid residues 1-911, and a pool of inserts of the 3' end clones (PL31-MD6-Pc4b) coding for residues 912-1685 and the 3' end untranslated region (10) . In order to characterize the extent of the deletions, some patient DNAs were hybridized with genomic probes: an EcoRI genomic fragment in pUC 18, LA226-E1, containing the first exon of both COL4A5 and COL4A6, the intergenic region, 140 bp of genomic sequences downstream COL4A6 exon 1 and 0.4 kb of genomic sequences downstream COL4A5 exon 1 (13, 18) , and the genomic phage vector clones MG3, F7, F8 (19) . Southern blotting and hybridization were performed as described previously (18) .
PCR. For analyzing mutations in some individuals, exon-specific PCR primers were made based on the published sequence (19; see also Table 1 ). PCR reactions, using 50 ng ofpatient DNA, were performed as described below for the nested cDNA-PCR.
RNA preparation and reverse transcription. Total cellular RNA was extracted from EBV-immortalized lymphoblastoid cell lines or PBL as described (20) . The cDNA was synthetized by random priming using hexanucleotide primers as template for the reverse transcriptase. Samples (500 ng) of total lymphoblast or PBL RNA in water were incu- ('fln Ar. The sizes of the bands observed with the seven cDNA probes with PstI and EcoRI are indicated in Table II 14 patient DNAs cleaved with the four enzymes were shown to lack normal bands hybridizing to one or several COL4A5 cDNA probes, suggesting major rearrangements of the COL4A5 gene in these patients. Six of them (S.D., F.D., J.T., B.F., F.C., F.P.) were partially described elsewhere ( 18, 22) .
Complete deletion. In patient L.T. we observed a complete absence of hybridization of all the cDNA probes and of the LA226-E 1 and MG3 genomic probes as well. This pattern indicates a complete deletion of the COL4A5 gene extending at least from 0.7 kb upstream ofthe 5' end ofthe cDNA and 10 kb downstream of the 3' end.
5' end deletions. Five patients (S.D., F.D., J.T., N.P., Y.T.) lacked the 2-kb PstI and 1.4-kb EcoRI restriction fragments hybridizing to the JZ4 probe and including exon 1 ( 13) . Furthermore, the EcoRI Southern blots ofthese five patients exhibited no signal with the LA226-E 1 genomic probe, demonstrating major deletions ofthe 5' part ofthe COL4A5 gene with a 5' breakpoint located upstream of the COL4A5 cDNA. Patients F.D., J.T., and N.P. had no other abnormality with all the cDNA probes, meaning that the deletion at its 3' end encompasses only the first COL4A5 exon. For patients S.D. and Y.T., the patterns observed with the different probes show that the deletion extends to exon 18 for patient S.D., and that the 3' deletion breakpoint lies in the region detected by the HT14-3 probe around exon 30 for patient Y.T.
Intragenic deletions. Eight patients (M.B., F.C., A.C., J.C., B.F., E.C., S.L., F.P.) lacked combination of restriction fragments hybridizing to one or several cDNA probes, suggesting completely intragenic COL4A5 deletions. The patterns of hybridization observed with the different COL4A5 cDNA probes, and with the genomic probes F7 and F8 in patients J.C., S.L., and F.P., as well as PCR amplification of genomic DNA for exons 38, 42 , and 45 (see Table I for primers' sequences), allowed us to precize to some extent the size of the deletions (Table II and Fig. 2) .
Thus The putative protein product could have been deduced from the results ofSouthern blotting and PCR amplification ofgenomic DNA in two patients with intragenic deletions (B.F. and E.C.). In these cases, the deletion would result in a frameshift mRNA and lead to a very short protein containing only the 7S domain and 77 amino acids of the amino-terminal part of the collagenous domain in the former, and to a truncated protein missing the entire noncollagenous domain and 305 amino acids of the carboxy-terminal part of the collagenous domain in the latter. On the basis of the suggested rearrangements in the COL4A5 gene of four other patients (J.C., A.C., S.L., and F.P.), we have screened by PCR amplification different portions of the COL4A5 mRNA from cultured lymphoblastoid cell lines or PBL using primers flanking the suspected deleted exons (see Table I for the sequence of the primers). Fig. 3 shows the results of the cDNA-PCR amplification and Fig. 4 the sequence of the pathological transcripts. Amplification of PBL RNA from patient J.C. with primers JC3 and JC4 (Fig. 3 B, lane 1) resulted in a 243-bp fragment, compared to an unamplified expected fragment of 3,570 bp. Sequence analysis confirmed splicing of exon 1 to exon 37, leading to a dramatically shortened in-frame transcript. The protein product would lack two-thirds of the amino-terminal part of the collagenous domain. Patient A.C. showed a 1,005-bp product instead ofthe normal 1,059 bp with primers JC3 and B4 (Fig. 3 B, lanes 2  and 3) . Sequence analysis showed absence ofexon 17 (Fig. 4) , maintaining an open reading frame. The truncated protein would lack 18 amino acids, from Gly-3 13 to Lys-330, between interruptions IV and V ofthe collagenous domain. The Gly-X-Y sequence characteristic of the collagenous domain would be preserved. Amplification of patient S.L. RNA with primers SL3 and SL4 (Fig. 3 A) yielded a PCR product of222 bp (Fig. 3  B, lane 4) vs. 639 bp in the control (lane 5), consistent with the loss of exons 38-41. Sequence analysis (Fig. 4) amino acids (Tyr-1126 to Pro-1263) in the collagenous domain of the a5 (IV) chain, with preservation of a repetitive though truncated Gly-X-Y sequence. With the same primers, amplification ofpatient F.P. RNA gave a 460-bp product (Fig.  3 B, lane 6 ) as compared to the 639-bp control. Sequence analysis (Fig. 4) showed splicing of exon 37 to exon 40 as expected from the size of the PCR product. The in frame transcript would code for a truncated a5(IV) chain lacking 60 amino acids from Tyr-1126 to Pro-1184 in the collagenous domain.
Determination ofcarrier status in females and origin ofmutations
Family members DNAs of five patients with deletions (four with altered size fragments) have been examined. In family N.P., densitometry analysis demonstrated that the asymptomatic mother's DNA displays the two copies of exon 1 (data not shown), suggesting a de novo mutation in the propositus. In family Y.T. (Fig. 5 A) , the patient's DNA lacks the 8-and 4.1-kb normal fragment and shows a 7-kb junction fragment, whereas the father and the maternal grandmother exhibit a ,5~4 (Fig. 5 B) , in the affected mother's DNA, both the normal 15-kb TaqI and the abnormal 1-kb TaqI fragments are present with HT 14-2, whereas the junction fragment is not detected in the two sisters' DNA. Therefore, they could be assigned as noncarrier with certainty. In family F.P. (Fig. 5 C) , the mother's DNA displayed the same abnormal 14-kb fragment as her son's associated with the normal allele, whereas the maternal grandmother and the two maternal aunts displayed a normal pattern, indicating that a new mutation arose in the mother. In family A.C. (Fig. 5 D) , the two affected brothers have an abnormal 11.7-kb fragment, while the three young sisters display a normal pattern and could be ascertained as noncarrier.
Correlations between genotypes and phenotypes history. The five others were detected in 7-14-yr-old children whose AS could not be assigned to the juvenile-or adult-type categories. These children likely have juvenile-type AS as suggested by the early onset of renal and extrarenal symptoms. On the contrary, the point mutation with loss of the MspI site was found in a family with adult-type AS.
The clinical and histopathological findings of the 14 patients with deletions are detailed in Table III . While eight of them fulfilled at least three of the criteria considered for AS diagnostic, only two of these criteria were present in the other six patients. Two of these six patients had leiomyomatosis and cataracts which is not considered as a typical ocular lesion of AS. Hearing loss was absent in three children (S.D., J.C., F.P.) but they were only 4-8 yr old and their affected relatives were all females, but also in a 24-yr-old patient (F.D.) with leiomyomatosis, on hemodialysis for 9 yr. The GBM distribution ofthe a3 and a4 chains of type IV collagen was documented in four patients with deletions (patients F.D., N.P., J.C., F.P.). In the four patients, no GBM labeling was observed with antia3(IV) and anti-a4(IV) antibodies. Tissue was not available for the patient with a point mutation.
All three patients (S.D., F.D., J.T.) who presented with diffuse esophageal leiomyomatosis associated with AS displayed deletion in the COL4A5 gene involving the 5' part of the gene and extending beyond the 5' end of the gene.
No mutation has been detected in the four patients belonging to kindreds affected with progressive hereditary nephritis without extrarenal symptoms.
Among the 15 patients in which we found alterations ofthe COL4A5 gene, 9 had renal transplantation (patients Y.T., M.B., F.D., E.C., L.T., S.L., B.D., and B.F.). Only one ofthem (L.T.) developed posttransplant anti-GBM disease with circulating anti-GBM antibodies and crescentic glomerulonephritis. This patient was the one with the complete deletion of the COL4A5 gene.
Discussion
With standard gel electrophoresis ofgenomic DNA, using a set of cDNA probes covering all the COL4A5 cDNA, we detected 15 different mutations, one single-base mutation (21 ) and 14 deletions, in 15 of 88 male AS patients. This finding corresponds to an overall deletion detection rate of 16%. The percentage is higher than the 1 over 18 observed by Barker et al. (23) and by Smeets et al. (24) , the 3/38 described by Boye et al. (25) , the 2/16 reported by Netzer et al. (26) , and the 5/46 reported by Renieri et al. (27) . However, this is the first report of a large series of AS patients tested with probes covering the entire COL4A5 cDNA, including the 5' end of the gene. This percentage of deletions found in this study is also higher than percentages reported in other hereditary disorders involving collagen genes, for example osteogenesis imperfecta (28). On the other hand, when the size ofthe COL4A5 gene ('-250 kb) is taken into account, the deletion rate does not appear to be excessively high in comparison with other X-linked loci such as the 186-kb FVIII:C locus (6% deletion rate), the 30-kb ornithine transcarbamylase locus (10% deletions), the 44-kb HPRT locus (10% deletions), and the 2,000-kb Duchenne muscular dystrophy (DMD) locus (67% deletions) (29) . However, it is possible that some deletions in an X-linked AS population involve the very recently characterized COL4A6 gene, and not COL4AS. By contrast with the relative high deletion detection rate, we found only one single-base mutation at an MspI restriction site. This emphasizes the need for other methods to detect mutations involving one or a few nucleotides. The 14 detected deletions were not confined to any particular region of the COL4A5 gene. One deletion involves the entire gene, five involve the 5' part of the gene with a 5' breakpoint located upstream, and eight are intragenic deletions covering different parts of the collagenous domain of COL4A5. However, four breakpoints out of the 14 deletions involve the first intron (in Table III Further studies will clarify whether or not this is due to a deletion hot-spot, possibly related to the large size of this intron. The extent ofintragenic deletions has been estimated with a combination ofgenomic and cDNA probes. However, the precise limits ofthe deletions could not have been delineated confidently in all of them, by Southern analysis alone, because of the limited number ofgenomic probes and the insufficient data available on the restriction pattern in some COL4A5 regions (e.g., exon 37). In order to precisely determine whether each deletion breakpoint occurs within introns or exons, and whether a deletion disrupts the reading frame, we used a nested amplification approach to amplify COL4AS illegitimate transcripts. It has been shown that any gene may be transcribed in any cell, whatever the tissue specificity, yielding a bona fide mature transcript ( 14) . Illegitimate transcription offers the invaluable advantage ofgiving access to abnormal tissue-specific transcripts using easily available cells. We have already taken advantage ofthis ectopic transcription to characterize the point mutation detected by the loss ofthe MspI site in one patient of this series (21 ) . But this technique is also a powerful method to characterize deletions, as shown in DMD (30) .
In this study, we sequenced the junction point oftruncated COL4A5 transcripts in PBL or EBV-established lymphoblasts from four patients with internal deletions ofthe COL4A5 gene. This permitted us to demonstrate that the four intragenic deletions that could be investigated at the mRNA level are intronintron mediated. Moreover we could ascertain the conservation of an open reading frame for all of them. By contrast, in two patients (B.F., E.C.) for whom lymphocyte RNA amplification was not available, a frameshift mRNA could be inferred from Southern blot analysis and genomic DNA exon amplification. It is noteworthy that both in-frame and frameshift deletions can lead to a similar severe phenotype, with extrarenal symptoms. Therefore, in opposition to DMD, no reading frame rule seems to exist in AS.
As the native a5 (IV) protein has not been isolated, we can only speculate on the structure ofthe mutated product. It must be absent for patient L.T. who has a complete deletion of the gene, and also for the five patients with deletions of the 5' part ofthe gene, involving the initiating codon and probably regulatory sequences. In patients with intragenic deletions, if the mRNA is stable enough to be translated, the protein product will be variably affected whether or not the open reading frame is maintained. The two out-of-frame deletions will result in severely altered proteins with truncated collagenous domains and absence of the NC 1 domain. The four in-frame deletions we have characterized at the mRNA level will be associated with truncated proteins lacking 18-1,055 amino acids in the collagenous domain, but with preservation of part of the Gly-X-Y repeat sequences and persistance of the noncollagenous NC I domain. Interestingly, deletion of as little as six Gly-X-Y triplets is sufficient to produce a severe juvenile phenotype with hearing loss (patient A.C.). This finding suggests that even a short truncation of the collagenous structure of an a(IV) chain can impair the normal alignment and assembly of three a( IV) chains to form the triple helical molecule and then alter the supramolecular collagen IV network thus resulting in structural changes ofthe GBM. Another possibility is that abnormal chains are retained within the rough endoplasmic reticulum, as has been shown for mutated a2 (I) collagen chain in osteogenesis imperfecta (31 ), and are not at all incorporated into a triplehelical molecule. Deletions, or major rearrangements of the COL4A5 gene, reported to date, were also observed in patients with juvenile AS (23) (24) (25) (26) (27) 32) . On the contrary, the single-base mutation reported here was detected in a family with adult type AS, like other point mutations (23, 24, 33) and a 10-bp insertion (34). However, single-base mutations may also be associated with severe forms of AS (34-38).
DNA analysis is helpful to correctly classify variants of AS on the basis ofthe molecular COL4A5 defects. We have shown that the syndrome characterized by DL, nerve deafness, cataract, and progressive nephritis also belongs to the AS spectrum ( 18) . Furthermore, the three patients of this study and three additional patients referred to our laboratory because of the DL-AS association (39) have a deletion in the 5' part of the gene extending beyond its 5' end. In three of them, it has been shown that the deletion 5' breakpoint lies within intron 2 of COL4A6 (13) . This suggests that DL may be due to the alteration of COL4A6, which is highly expressed in esophagus ( 13) or of a second gene involved in smooth muscle cell proliferation and located in intron 2 of COL4A6. Interestingly, several ofthe deletions we identified result in phenotypes which do not even fulfill the currently used diagnostic criteria for AS ( 15) . 6 among the 14 patients had only two criteria, whereas it has been suggested that at least three criteria are necessary for the diagnosis ( 15) . For example, patient F.D. has a juvenile-type AS without hearing loss 9 yr after he reached ESRF. This emphasizes the need for reclassification ofAS, based on both clinical and molecular criteria.
2 ofthe 15 mutations reported in this study were detected in patients without any family history of AS. In one of them, the mother was proved to be noncarrier. Furthermore, in two other families, the mutation was shown to have occurred in the proband's mother. Two other de novo mutations have been described (26, 40) . These findings confirm the previous estimation from Shaw et al. (41 ) , based on the decreased reproductive fitness ofaffected males, that up to 18% ofnewborns with a gene for AS represent new mutations. They underline the fact that the diagnosis ofAS, leading to molecular genetic investigations, has to be considered even in the absence of family history.
A puzzling immunohistochemical observation is the frequently abnormal distribution of the a3 and a4 chains of type IV collagen in X-linked AS patients (4, 5) , presumed to have mutations in the COL4A5 gene and hence an abnormal aS (IV) chain. Until now, no documented immunohistochemical studies have been reported in patients with proven COL4A5 mutations. In this study, the immunohistochemical analysis of the GBM distribution of collagen IV chains revealed the absence of the a3 and a4 chain antigens in four patients with COL4A5 deletions. This finding shows for the first time that structural changes in the a5(IV) chain can impair the incorporation of a3 (IV) and a4(IV) chains within the type IV collagen network, a hypothesis proposed by Kashtan et al. (42) . About 1-5% of transplanted AS male patients develop anti-GBM antibodies leading to severe crescentic glomerulonephritis and subsequent graft loss. The alloimmunization of AS patients has been considered as triggered by the introduction of GBM containing antigenic epitopes, located in the NC1 domain of type IV collagen, that are absent in the recipient (43, 44 (26) and is also associated with anti-GBM nephritis. However, other molecular lesions such as deletions involving exons coding for the NC 1 domain ofa5 (IV) and a point mutation affecting the 3' splicing site ofexon 38 were associated with the same complication (24, 33, 37) . Conversely, in our series, six transplanted patients (Table III) with major deletions, some ofthem presumably leading to the complete absence of the a5 (IV) chain, did not develop anti-GBM antibodies. It clearly shows that other factors, in addition to the genetic defect, are implicated in the occurrence of this allo-immunization.
Correct identification of carrier females is crucial for genetic counselling. We could detect altered-size fragments (junction fragments) in 8 of the 14 patients with deletion by standard Southern blotting, and thus we obtained a simple test to identify carrier females, as shown in four of these families (Fig. 5) . However, detection of carrier status is a difficult task in half of the cases since it has to be based on the hazardous interpretation of gene dosage. To overcome this problem, the detection of COL4A5 transcripts from PBL RNA could be used for rapid detection of female deletion carriers, as shown for the DMD gene (45) . Furthermore, this approach could make point mutation screening a practical proposition.
